A first-in-human (FIH) phase I study of IPH5301, an anti-CD73 monoclonal antibody (mAb), in patients with advanced solid tumors (AST) (CHANCES, NCT05143970)

被引：0
|
作者：
Beaufils, M. [1 ]
Mailliez, A. [2 ]
Sfumato, P. [3 ]
Vicier, C. [1 ]
Gross, M. Provansal [1 ]
Guerin, M. [1 ]
Chanez, B. [1 ]
Kotecki, N. [4 ]
Widemann, A. [5 ]
Panzolato, S. [6 ]
Chammard, A. Boyer [7 ]
Andre, P. [8 ]
Paturel, C. L.
Gouarne, C.
Awada, A. H.
Boher, J. M. [3 ]
Goncalves, A. [1 ]
机构：
[1] IPC Inst Paoli Calmettes, Med Oncol Dept, Marseille, France
[2] Ctr Oscar Lambret, Med Oncol Dept, Marseille, France
[3] IPC Inst Jules Bordet, Dept Clin Res, Brussels, Belgium
[4] Inst Jules Bordet, Oncol Med Dept, Brussels, Belgium
[5] Innate Pharma, Clin Pharmacol, Marseille, France
[6] Innate Pharma, Clin Operat, Marseille, France
[7] Innate Pharma, Marseille, France
[8] Innate Pharma, Res & Drug Dev, Marseille, France
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1062
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1003P
引用
收藏
页码：S682 / S683
页数：2
相关论文
共 50 条
  • [31] Phase I study of CNTO 95, a fully human monoclonal antibody (mAb) to αv integrins, in patients with solid tumors
    Jayson, GC
    Mullamitha, S
    Ton, C
    Valle, J
    Jackson, A
    Julyan, P
    Munteanu, MC
    Davis, HM
    Lang, Z
    Beckman, RA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 220S - 220S
  • [32] First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors
    Elena Elez, Maria
    Tabernero, Josep
    Geary, David
    Macarulla, Teresa
    Kang, S. Peter
    Kahatt, Carmen
    Soto-Matos Pita, Arturo
    Fernandez Teruel, Carlos
    Siguero, Mariano
    Cullell-Young, Martin
    Szyldergemajn, Sergio
    Ratain, Mark J.
    CLINICAL CANCER RESEARCH, 2014, 20 (08) : 2205 - 2214
  • [33] A phase I, first-in-human study of DS-1471 in patients with advanced/metastatic solid tumors
    Koganemaru, S.
    Yoshizuka, N.
    Mizuno, S.
    Hirai, S.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S531 - S531
  • [34] First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors
    Papadopoulos, Kyriakos P.
    Gluck, Larry
    Martin, Lainie P.
    Olszanski, Anthony J.
    Tolcher, Anthony W.
    Ngarmchamnanrith, Gataree
    Rasmussen, Erik
    Amore, Benny M.
    Nagorsen, Dirk
    Hill, John S.
    Stephenson, Joe, Jr.
    CLINICAL CANCER RESEARCH, 2017, 23 (19) : 5703 - 5710
  • [35] A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors.
    Sikic, Branimir I.
    Lakhani, Nehal J.
    Patnaik, Amita
    Shah, Sumit
    Chandana, Sreenivasa R.
    Rasco, Drew W.
    Colevas, A. Dimitrios
    O'Rourke, Timothy J.
    Papadopoulos, Kyriakos P.
    Fisher, George A.
    Chao, Mark
    Agoram, Balaji
    Chen, James Y.
    Huang, Jenny
    Axt, Matthew
    Majeti, Ravindra
    Weissman, Irving L.
    Takimoto, Chris H. M.
    Pegram, Mark D.
    Padda, Sukhmani Kaur
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] First-in-human (FIH) phase I data of HST-1011, an oral CBL-B inhibitor, in patients with advanced solid tumors
    Sanborn, R. E.
    Patel, M. R.
    Rodon, J.
    Thein, K. Z.
    Friedman, C.
    Levitz, D.
    Ngirailemesang, I.
    Goodman, A.
    Agarwal, P.
    Friedman, E.
    Danaee, H.
    Robell, K.
    Jaeger, S.
    Sun, H.
    Debanne, E.
    Dunn, J.
    Wright, E.
    Reilly, T.
    Luke, J. J.
    Redig, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S675 - S676
  • [37] Updated findings of a first-in-human, phase I study of margetuximab (M), an Fc-optimized chimeric monoclonal antibody (MAb), in patients (pts) with HER2-positive advanced solid tumors.
    Burris, Howard A.
    Giaccone, Giuseppe
    Im, Seock-Ah
    Bauer, Todd Michael
    Oh, Do-Youn
    Jones, Suzanne Fields
    Nordstrom, Jeffrey L.
    Li, Hua
    Carlin, David A.
    Baughman, Jan E.
    Lechleider, Robert Joseph
    Bang, Yung-Jue
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] First-in-human evaluation of the human monoclonal antibody vantictumab (OMP-18R5; anti-Frizzled) targeting the WNT pathway in a phase I study for patients with advanced solid tumors
    Smith, David C.
    Rosen, Lee S.
    Chugh, Rashmi
    Goldman, Jonathan Wade
    Xu, Lu
    Kapoun, Ann
    Brachmann, Ranier K.
    Dupont, Jakob
    Stagg, Robert J.
    Tolcher, Anthony W.
    Papadopoulos, Kyriakos P.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors
    van Oordt, C. Willemien Menke-van der Houven
    Gomez-Roca, Carlos
    van Herpen, Carla
    Coveler, Andrew L.
    Mahalingam, Devalingam
    Verheul, Henk M. W.
    van der Graaf, Winette T. A.
    Christen, Randolph
    Ruettinger, Dominik
    Weigand, Stefan
    Cannarile, Michael A.
    Heil, Florian
    Brewster, Michael
    Walz, Antje-Christine
    Nayak, Tapan K.
    Guarin, Ernesto
    Meresse, Valerie
    Le Tourneau, Christophe
    ONCOTARGET, 2016, 7 (48) : 80046 - 80058
  • [40] A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors
    Oh, Do-Youn
    Lee, Keun-Wook
    Han, Sae-Won
    Kim, Jin Won
    Shin, Jung-Won
    Jo, Seong-Jin
    Won, Jonghwa
    Hahn, Seokyung
    Lee, Howard
    Kim, Woo Ho
    Bang, Yung-Jue
    ONCOLOGIST, 2019, 24 (08): : 1037 - +
12345